Ozempic Receives FDA Approval To Treat Kidney Disease
1. FDA approves Ozempic for chronic kidney disease, expanding its use. 2. Over 35.5 million Americans may benefit from this treatment. 3. Novo Nordisk aims to address cardiovascular-kidney-metabolic syndrome. 4. Ozempic's price negotiations under Medicare Part D start in 2025. 5. NVO shares fell 2.65% to $85.19 after the announcement.